Biogen’s Aduhelm rollout goes from bad to worse
pharmaphorum
OCTOBER 21, 2021
Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. Pushback from doctors in particular is causing anxiety for investors, as that may not be affected much if CMS opts to approve reimbursement, and shares in the company fell a little over 6% following the results announcement.
Let's personalize your content